Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased BioScrip, Inc. (“BioScrip” or the “Company”) (NasdaqGS:BIOS) common stock between August 8, 2011 and September 20, 2013. For more information, click here: http://zlk.9nl.com/bioscrip-bios/. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or omitted materially adverse facts about the Company’s business, operations and prospects. In particular, it is alleged that the Company violated the False Claims Act and other federal and state statutes by improperly distributing the Novartis Pharmaceuticals Corporation product Exjade through its specialty pharmacy operations. On September 23, 2013, the Company acknowledged the receipt of a civil investigate demand issued by the US Attorney’s Office for the Southern District of New York and the receipt of a subpoena from the New York State Attorney General’s Medicaid Fraud Control Unit. Upon this news, shares of BioScrip fell more than 23 percent. If you suffered a loss in BioScrip you have until November 29, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/bioscrip-bios/. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.